Clinical Trials Browser

Phase 2 × Adenoma, Islet Cell × Specimen Handling × Clear all

NCT06202066 2026-05-28

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Phase 2 Recruiting

Adenoma, Islet Cell